Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Autoimmune Disorders

Free Subscription Articles published in J Neuroimmunol Retrieve available abstracts of 152 articles: HTML format

Single Articles

August 2025
1. HOSHINA Y, Smith TL, Mstat AD, Wong KH, et al
   An updated, comprehensive meta-analysis of the treatment of anti-NMDAR encephalitis: Analysis, equipoise, and the urgent need for evidence over anecdote.
   J Neuroimmunol. 2025;405:578651.
   PubMed     Abstract available
   
   
   
2. MIYAKE S, Katsura Y, Baba M, Tomizawa-Shinohara H, et al
   Anti-IL-6R antibody treatment changes microglial phenotype in AQP4 peptide-immunized mice, leading to suppression of myelitis severity.
   J Neuroimmunol. 2025;405:578644.
   PubMed     Abstract available
   
   
   July 2025
3. INOUE Y, Fujii T, Kashu KY, Watanabe M, et al
   Associations between serum levels of alpha-calcitonin gene-related peptide and clinical features of neuromyelitis optica spectrum disorders.
   J Neuroimmunol. 2025;404:578615.
   PubMed     Abstract available
   
   
   
4. SANDWEISS AJ, Rosen J, Aduru C, Chandrasekar A, et al
   MOGAD optic neuritis after mild head/orbital trauma in six children.
   J Neuroimmunol. 2025;404:578605.
   PubMed     Abstract available
   
   
   
5. JAHANSOOZ JR, Kameoka AM, Shibuya J, Abramowitz J, et al
   Recurrent anti-NMDA receptor encephalitis in first-trimester pregnancy with initially antibody-negative CSF.
   J Neuroimmunol. 2025;404:578602.
   PubMed     Abstract available
   
   
   June 2025
6. WELSH NC, DiSano KD, Pike SC, Linzey M, et al
   Network analysis of intrathecally synthesized proteins to unravel mechanisms of disease course in multiple sclerosis.
   J Neuroimmunol. 2025;406:578678.
   PubMed     Abstract available
   
   
   
7. NIBBER A, Wills B, Pettingill P, Fox H, et al
   Evolution and significance of neuronal surface autoantibodies after Japanese encephalitis.
   J Neuroimmunol. 2025;406:578671.
   PubMed     Abstract available
   
   
   
8. WON J, Kim J, Qiao F, Singh AK, et al
   Therapeutic potential of S-nitrosoglutathione reductase inhibitor in B cell-driven experimental autoimmune encephalomyelitis.
   J Neuroimmunol. 2025;406:578673.
   PubMed     Abstract available
   
   
   
9. NASEER MA, Hegazy M, El-Mehdawy KM, Ashraf H, et al
   Serum levels of tumor necrosis factor and TNFRSF1A gene polymorphisms in Egyptian multiple sclerosis patients: the influence on susceptibility and severity.
   J Neuroimmunol. 2025;406:578672.
   PubMed     Abstract available
   
   
   
10. PEREIRA DA, Mariano M, Marcon N, Maia MM, et al
    A rare neuroendocrine presentation in pediatric anti-glutamic acid decarboxylase autoimmunity: Case report and literature review.
    J Neuroimmunol. 2025;406:578670.
    PubMed     Abstract available
    
    
    
11. CAKAN M, Demirel E, Cimen B, Ozen NPA, et al
    Comparison of clinical features of aquaporin-4 positive neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein associated disorder (MOGAD), and double seronegative NMOSD - A single center experience.
    J Neuroimmunol. 2025;403:578591.
    PubMed     Abstract available
    
    
    
12. ABBOUD H, Steingo B, Vargas D, Patel J, et al
    Satralizumab treatment in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder after rituximab treatment: A case series.
    J Neuroimmunol. 2025;403:578585.
    PubMed     Abstract available
    
    
    
13. ZIVOTIC I, Kolic I, Stefanovic M, Stefanovic NM, et al
    Association of TGFB1 and IFNB1 expression levels in peripheral blood mononuclear cells with multiple sclerosis with respect to proximal rs1800469 and rs2275888 eQTLs.
    J Neuroimmunol. 2025;406:578666.
    PubMed     Abstract available
    
    
    
14. JOHNSON CB, Fehmi J, Rinaldi S
    The immunology and neuropathology of the autoimmune nodopathies.
    J Neuroimmunol. 2025;406:578665.
    PubMed     Abstract available
    
    
    
15. SAGHARICHI M, Aalipour MA, Eghbal E, Javandoust Gharehbagh F, et al
    Autoimmune encephalitis and delayed diagnosis in common variable immunodeficiency: A case report and review of literature.
    J Neuroimmunol. 2025;406:578662.
    PubMed     Abstract available
    
    
    May 2025
16. WEIGEL J, Appeltshauser L, Sommer C, Doppler K, et al
    Proprioceptive endings at muscle spindles as a possible target of autoantibodies.
    J Neuroimmunol. 2025;405:578648.
    PubMed     Abstract available
    
    
    
17. YAO ZY
    Reflections on the influence of seasonal and environmental factors in myasthenia gravis.
    J Neuroimmunol. 2025;405:578645.
    PubMed    
    
    
    
18. MAKHARIA A, Agarwal A, Garg D, Garg A, et al
    The dilemma of demyelination: A case of Schilder's disease with insights from literature.
    J Neuroimmunol. 2025;402:578584.
    PubMed     Abstract available
    
    
    
19. WANG Y, Huan X, Song J, Zhu X, et al
    Clinical outcome and peripheral CD4(+) T profile in impending myasthenic crisis: A prospective cohort study.
    J Neuroimmunol. 2025;402:578572.
    PubMed     Abstract available
    
    
    April 2025
20. DEFFENBAUGH JL, Jung KJ, Murphy SP, Liu Y, et al
    Corrigendum to "Novel model of multiple sclerosis induced by EBV-like virus generate a unique B cell population" [Journal of Neuroimmunology volume 394 (2024) 578408].
    J Neuroimmunol. 2025;404:578625.
    PubMed    
    
    
    
21. ONISHI Y, Uzawa A, Yasuda M, Akamine H, et al
    Elevated serum levels of IL-10 family and IL-12 family cytokines in myasthenia gravis.
    J Neuroimmunol. 2025;404:578621.
    PubMed     Abstract available
    
    
    
22. MASI F, Al Qudsi S, Visigalli D, Zardini E, et al
    Oligoclonal IgM band patterns in multiple sclerosis: A two-center study.
    J Neuroimmunol. 2025;404:578622.
    PubMed     Abstract available
    
    
    
23. NAGAPPA M, Mondal S, Rajeevan S, Pradeepkumar B, et al
    Exploring the role of altered oxi-inflammasome activity in the immunobiology of inflammatory neuropathies.
    J Neuroimmunol. 2025;401:578556.
    PubMed     Abstract available
    
    
    
24. LI Q, Liu B, Guan Y, Wang Y, et al
    Double filtration plasmapheresis in autoimmune gastritis with subacute combined degeneration of the spinal cord: A case report.
    J Neuroimmunol. 2025;403:578618.
    PubMed     Abstract available
    
    
    
25. ZHARIKOV Y, Shitova A, Melnikova P, Voloshin I, et al
    Autoantibody-mediated disorders of the central and peripheral nervous system: Overview Infection.
    J Neuroimmunol. 2025;403:578616.
    PubMed     Abstract available
    
    
    
26. EL MAHDAOUI S, Husted SR, Hansen MB, Cobanovic S, et al
    Corrigendum to "Cerebrospinal fluid soluble CD27 is associated with CD8+ T cells, B cells and biomarkers of B cell activity in relapsing-remitting multiple sclerosis" [Journal of neuroimmunology vol. 381 (2023): 578128].
    J Neuroimmunol. 2025;403:578607.
    PubMed    
    
    
    
27. PETROU P, Kassis I, Levi Y, Yaghmour N, et al
    Kinetics of serum NFL and GFAP and changes in cognitive functions, in MS patients treated with repeated administrations of autologous mesenchymal stem cells (MSC-NG01).
    J Neuroimmunol. 2025;403:578613.
    PubMed     Abstract available
    
    
    
28. TRAN GT, Bedi S, Rakesh P, Verma ND, et al
    Autoantigen and IL-2 activated CD4(+)CD25(+)T regulatory cells are induced to express CD8 and are autoantigen specific in inhibiting experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2025;404:578611.
    PubMed     Abstract available
    
    
    
29. ZHANG Z, Wu J, Xu D, Zhao S, et al
    Clinical characteristics and immunotherapy efficacy in autoimmune-associated benign epilepsy with centrotemporal spikes: A prospective cohort study.
    J Neuroimmunol. 2025;404:578603.
    PubMed     Abstract available
    
    
    
30. MARQUES RF, Pedrosa DA, Talim N, Lemos JC, et al
    Relapsing-remitting multiple sclerosis as a potential consequence of thalidomide treatment: A case report.
    J Neuroimmunol. 2025;404:578606.
    PubMed     Abstract available
    
    
    
31. STAYKOVA M, Bruestle A
    Nitric oxide and experimental autoimmune encephalomyelitis review.
    J Neuroimmunol. 2025;404:578586.
    PubMed     Abstract available
    
    
    March 2025
32. WANG Z, Du X, Wang Q, Zhang Y, et al
    Ofatumumab for the treatment of COVID-19-associated autoimmune encephalitis: A case report.
    J Neuroimmunol. 2025;403:578590.
    PubMed     Abstract available
    
    
    
33. ZEYDAN B, Neyal N, Nathoo N, Rangachari M, et al
    Effects of androgen modifying therapies on disease activity in older men with multiple sclerosis.
    J Neuroimmunol. 2025;403:578589.
    PubMed     Abstract available
    
    
    
34. CHUANG TY, LaBarre BA, Corbali O, Healy BC, et al
    Endocrine disrupting chemicals in early MS disease activity.
    J Neuroimmunol. 2025;400:578546.
    PubMed     Abstract available
    
    
    February 2025
35. KHEDR EM, Hassan MM, Ezzeldeen MY, El-Kady MS, et al
    Motor symptoms at onset and manual dexterity predict cognitive impairment in drug-naive individuals with multiple sclerosis.
    J Neuroimmunol. 2025;401:578571.
    PubMed     Abstract available
    
    
    
36. SHAHBAKHSH M, Jalousian F, Hosseini SH, Naser Moghadasi A, et al
    Toxocara canis-originated recombinant C-type lectin improves the disability scores of experimental autoimmune encephalomyelitis in murine in vivo models.
    J Neuroimmunol. 2025;402:578569.
    PubMed     Abstract available
    
    
    
37. KUO PC, Zhao Z, Scofield BA, Paraiso HC, et al
    Benzoylacetonitrile as a novel anti-inflammatory compound on attenuating microglia and encephalitogenic T cell activation in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2025;401:578557.
    PubMed     Abstract available
    
    
    
38. HE D, Zhou Y, Zhang Y, Zhang J, et al
    Response of refractory residual ocular symptoms to efgartigimod in generalized myasthenia gravis: A real-world case series.
    J Neuroimmunol. 2025;401:578558.
    PubMed     Abstract available
    
    
    
39. GHOSH S, Bhaskar R, Singh KK, Sinha JK, et al
    Immunotherapy challenges and potential role of unclassified antibodies in complex autoimmune encephalitis.
    J Neuroimmunol. 2025;401:578555.
    PubMed    
    
    
    
40. LIU Y, Sun H, Xu Y, Xuan B, et al
    Identification and characteristics of a novel CD8alphaalpha T cell subset in a refractory myasthenia gravis patient.
    J Neuroimmunol. 2025;400:578551.
    PubMed     Abstract available
    
    
    
41. ZHANG M, Zhu X, Yu L, Fang Z, et al
    Pediatric anti-CaValpha2delta autoimmune encephalitis: A case report and literature review.
    J Neuroimmunol. 2025;401:578550.
    PubMed     Abstract available
    
    
    
42. YAN Z, Yang X, Lin B, Zhu Q, et al
    Brain network alteration was associated with 'no evidence of disease activity' status in patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2025;400:578549.
    PubMed     Abstract available
    
    
    
43. CULINA S, Commere PH, Turc E, Jouy A, et al
    MicroRNA signatures of CD4(+) T cell subsets in healthy and multiple sclerosis subjects determined by small RNA-sequencing.
    J Neuroimmunol. 2025;401:578531.
    PubMed     Abstract available
    
    
    January 2025
44. RANDHAWA G, Mobarakabadi M, D'Mello C, Morch MT, et al
    Targeting extracellular matrix components to attenuate microglia neuroinflammation: A study of fibulin-2 and CSPGs in a model of multiple sclerosis.
    J Neuroimmunol. 2025;400:578533.
    PubMed     Abstract available
    
    
    
45. FALK KK, Cabrera LA, Junker R, Leypoldt F, et al
    Serum NfL predicts outcome and secondary autoimmunity in herpes-simplex encephalitis.
    J Neuroimmunol. 2025;400:578528.
    PubMed     Abstract available
    
    
    
46. ETEMADIFAR M, Aghili A, Shojaei S, Alaei SA, et al
    Balo concentric sclerosis, an emerging variant of multiple sclerosis: A case-series and literature review.
    J Neuroimmunol. 2025;400:578527.
    PubMed     Abstract available
    
    
    
47. LI Y, Chen P, Huang X, Huang H, et al
    Corrigendum to "Pathogenic Th17 cells are a potential therapeutic target for tacrolimus in AChR-myasthenia gravis patients" [Journal of Neuroimmunology. 2024 Nov 15:396:578464].
    J Neuroimmunol. 2025 Jan 16:578526. doi: 10.1016/j.jneuroim.2025.578526.
    PubMed    
    
    
    
48. VORASOOT N, Halfdanarson TR, Madigan NN, Dubey D, et al
    Pre-existing Lambert-Eaton Myasthenic Syndrome and Scleroderma in a Patient with Neuroendocrine Carcinoma Undergoing Immune Checkpoint Inhibitor Cancer Immunotherapy.
    J Neuroimmunol. 2025;398:578485.
    PubMed     Abstract available
    
    
    
49. GULEC B, Everest E, Uygunoglu U
    Letter to the Editor Regarding "Spinocerebellar ataxia masquerading as multiple sclerosis, a case report".
    J Neuroimmunol. 2025;399:578523.
    PubMed    
    
    
    
50. FALSO S, Zara P, Marini S, Puci M, et al
    Seasonal variation in myasthenia gravis incidence.
    J Neuroimmunol. 2025;399:578524.
    PubMed     Abstract available
    
    
    December 2024
51. GURSKI CJ, Hajiyeva Z, Veltri AJ, Fenton K, et al
    Corrigendum to "Elevated frequencies of activated memory B cells in multiple sclerosis are reset to healthy control levels are B cell depletion with Ocrelizumab" [J. Neuroimmunol. 339:578502 (2024)].
    J Neuroimmunol. 2024;399:578519.
    PubMed    
    
    
    
52. ITOH C, Swart G, St Louis E, Gandhi M, et al
    IgLON5 autoimmunity secondary to immune checkpoint inhibitor.
    J Neuroimmunol. 2024;399:578516.
    PubMed     Abstract available
    
    
    
53. HERNANDEZ RUIZ JJ, Romero Malacara AMC, Lopez Mota LA, Perez Guzman MJ, et al
    Therapeutic development towards T follicular helper cells as a molecular target in myasthenia gravis disease.
    J Neuroimmunol. 2024;399:578503.
    PubMed     Abstract available
    
    
    
54. LIANG Y, Huang J, Zhang X, Xu F, et al
    Quantitative assessment of thalamic damage and serum neurofilament light chain in relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2024;399:578504.
    PubMed     Abstract available
    
    
    
55. GILLIGAN M, O'Donnell L, Westbrook A, Tubridy N, et al
    A complex and severe encephalitis associated with four co-existing neuronal cell-surface autoantibodies.
    J Neuroimmunol. 2024;399:578501.
    PubMed     Abstract available
    
    
    
56. GURSKI CJ, Hajiyeva Z, Veltri AJ, Fenton K, et al
    Elevated frequencies of activated memory B cells in multiple sclerosis are reset to healthy control levels after B cell depletion with Ocrelizumab.
    J Neuroimmunol. 2024;399:578502.
    PubMed     Abstract available
    
    
    November 2024
57. OZKOSAR A, Oktelik FB, Gelmez MY, Ozturk Erden S, et al
    Retinoic acid modulates peripheral blood helper innate lymphoid cell composition in vitro in patients with multiple sclerosis.
    J Neuroimmunol. 2024;398:578489.
    PubMed     Abstract available
    
    
    
58. KIM S, Lee S, Chung YH, Ju H, et al
    Myelin oligodendrocyte glycoprotein antibody-associated disease with histopathologic features of primary CNS angiitis without demyelination: Case report and literature review.
    J Neuroimmunol. 2024;396:578467.
    PubMed     Abstract available
    
    
    
59. LAI R, Wu Z, Wang H, Feng L, et al
    Ofatumumab treatment for severe refractory anti-NMDAR encephalitis: A case series.
    J Neuroimmunol. 2024;396:578458.
    PubMed     Abstract available
    
    
    October 2024
60. FAN Z, Li J, Zhang Y, Kang J, et al
    Kidney injury: An overlooked manifestation in autoimmune encephalitis.
    J Neuroimmunol. 2024;397:578472.
    PubMed     Abstract available
    
    
    
61. YASUDA M, Uzawa A, Kuwabara S, Suzuki S, et al
    Corrigendum to "Clinical features and outcomes of patients with muscle-specific kinase antibody-positive myasthenia gravis in Japan" [Journal of Neuroimmunology 385 (2023) 578241].
    J Neuroimmunol. 2024;397:578465.
    PubMed    
    
    
    
62. CHENG X, Cui C, Shen S, Li Z, et al
    Probiotics-regulated lithocholic acid suppressed B-cell differentiation in neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2024;395:578422.
    PubMed     Abstract available
    
    
    
63. HONG Y, Gao L, Huang SQ, Liu S, et al
    Efgartigimod as a fast-acting add-on therapy in manifest and impending myasthenic crisis: A single-center case series.
    J Neuroimmunol. 2024;395:578431.
    PubMed     Abstract available
    
    
    
64. LI Y, Chen P, Huang X, Huang H, et al
    Pathogenic Th17 cells are a potential therapeutic target for tacrolimus in AChR-myasthenia gravis patients.
    J Neuroimmunol. 2024;396:578464.
    PubMed     Abstract available
    
    
    September 2024
65. LIU Y, Yang CL, Zhao XL, Zhao YJ, et al
    Characteristics of anti-contactin1 antibody positive autoimmune nodopathies combined with membranous nephropathy.
    J Neuroimmunol. 2024;396:578460.
    PubMed     Abstract available
    
    
    
66. BAI G, Bai Y, Guan H, Ren H, et al
    A case report of lymphoproliferative disease in brain following therapies with mycophenolate Mofetil and Fingolimod and literature review.
    J Neuroimmunol. 2024;394:578410.
    PubMed     Abstract available
    
    
    
67. YASUDA M, Uzawa A, Onishi Y, Handa H, et al
    Elevated serum levels of C-terminal agrin fragment in acetylcholine receptor antibody-positive myasthenia gravis.
    J Neuroimmunol. 2024;396:578455.
    PubMed     Abstract available
    
    
    
68. BAXTER L, Hopkins S, O'Connor KC, Pham MC, et al
    Fluorescence-detection size-exclusion chromatography specifically detects autoantibodies targeting the ganglionic acetylcholine receptor in patients with autoimmune autonomic ganglionopathy.
    J Neuroimmunol. 2024;396:578454.
    PubMed     Abstract available
    
    
    
69. HUANG YF, Briggs CM, Gokhale S, Punga AR, et al
    Elevated C1s/C1-INH in serum and plasma of myasthenia gravis patients.
    J Neuroimmunol. 2024;396:578447.
    PubMed     Abstract available
    
    
    
70. SAMIM MM, Mandal R, Joy J, Dhar D, et al
    Spectrum of Auto-antibodies in NMO and MOG Associated CNS Demyelination- The SANMAD Study.
    J Neuroimmunol. 2024;396:578446.
    PubMed     Abstract available
    
    
    
71. XU Y, Wei Y, Shi Z, Yin F, et al
    Multimodal magnetic resonance longitudinal study on the deep gray matter in multiple sclerosis patients with teriflunomide.
    J Neuroimmunol. 2024;396:578445.
    PubMed     Abstract available
    
    
    August 2024
72. ABOSEIF A, Amin M, Macaron G, Ontaneda D, et al
    Discordance of reported multiple sclerosis clinical course amongst patients and providers.
    J Neuroimmunol. 2024;395:578443.
    PubMed     Abstract available
    
    
    
73. BILEK F, Ercan Z, Deniz G, Ozgul S, et al
    High-intensity intermittent exercise increases serum levels of chitinase 3-like protein-1 and matrix metalloproteinase-9 in persons with multiple sclerosis.
    J Neuroimmunol. 2024;395:578434.
    PubMed     Abstract available
    
    
    
74. CHEN P, Chen J, Huang H, Liu W, et al
    Conventional dendritic cells are more activated in the hyperplastic Thymus of myasthenia gravis patients.
    J Neuroimmunol. 2024;395:578441.
    PubMed     Abstract available
    
    
    
75. WRIGHT MA, Guasp M, Lachner C, Day GS, et al
    Authors' response to letter to the editor: Electroconvulsive therapy in N-methyl-d-aspartate receptor encephalitis.
    J Neuroimmunol. 2024;393:578405.
    PubMed    
    
    
    
76. KRIEGER S, Zarif M, Bumstead B, Buhse M, et al
    Evaluating the effect of dimethyl fumarate on subclinical biomarkers in a real-world patient cohort.
    J Neuroimmunol. 2024;393:578397.
    PubMed     Abstract available
    
    
    
77. SHARMA M, Pal P, Gupta SK, Potdar MB, et al
    Microglial-mediated immune mechanisms in autoimmune uveitis: Elucidating pathogenic pathways and targeted therapeutics.
    J Neuroimmunol. 2024;395:578433.
    PubMed     Abstract available
    
    
    
78. LEHIKOINEN J, Strandin T, Parantainen J, Nurmi K, et al
    Fibrinolysis associated proteins and lipopolysaccharide bioactivity in plasma and cerebrospinal fluid in multiple sclerosis.
    J Neuroimmunol. 2024;395:578432.
    PubMed     Abstract available
    
    
    
79. YARIMI JM, Sandweiss AJ, Salazar KP, Massrey C, et al
    IT-DEX and B cell depletion in a child with anti-GAD 65 autoimmune encephalitis presenting as NORSE: A case report.
    J Neuroimmunol. 2024;395:578430.
    PubMed     Abstract available
    
    
    
80. ETEMADIFAR M, Alaei SA, Sedaghat N, Ghandehari AH, et al
    TEMPORARY REMOVAL: Pure spinal multiple sclerosis: A case series of a possible new entity.
    J Neuroimmunol. 2024 Aug 8:578429. doi: 10.1016/j.jneuroim.2024.578429.
    PubMed    
    
    
    
81. TORTOSA-CARRERES J, Cubas-Nunez L, Piqueras M, Castillo-Villalba J, et al
    Evaluating the complement C1q levels in serum and cerebrospinal fluid in multiple sclerosis patients: Could it serve as a valuable marker in clinical practice?
    J Neuroimmunol. 2024;394:578428.
    PubMed     Abstract available
    
    
    July 2024
82. LI YJ, Zhang XY, Zhang WJ, Han YL, et al
    Proteomics analysis of immune response-related proteins in Guillain-Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
    J Neuroimmunol. 2024;394:578423.
    PubMed     Abstract available
    
    
    
83. WUERCH EC, Mirzaei R, Yong VW
    Niacin produces an inconsistent treatment response in the EAE model of multiple sclerosis.
    J Neuroimmunol. 2024;394:578421.
    PubMed     Abstract available
    
    
    
84. DEFFENBAUGH JL, Jung KJ, Murphy SP, Liu Y, et al
    Novel model of multiple sclerosis induced by EBV-like virus generates a unique B cell population.
    J Neuroimmunol. 2024;394:578408.
    PubMed     Abstract available
    
    
    
85. YOKOTE H, Miyazaki Y, Fujimori J, Nishida Y, et al
    Characterization of Japanese multiple sclerosis patients with progression independent of relapse activity: A 2-year multicenter cohort study.
    J Neuroimmunol. 2024;394:578407.
    PubMed     Abstract available
    
    
    
86. PEGAT A, Chanson JB, Lozeron P, Joubert B, et al
    Identification of rare variants in the FBXO38 gene of patients with chronic inflammatory demyelinating polyradiculoneuropathy.
    J Neuroimmunol. 2024;392:578381.
    PubMed     Abstract available
    
    
    
87. WRIGHT MA, Guasp M, Lachner C, Day GS, et al
    Electroconvulsive therapy in N-methyl-d-aspartate receptor encephalitis: A retrospective cohort and scoping review of literature.
    J Neuroimmunol. 2024;392:578369.
    PubMed     Abstract available
    
    
    
88. FONSECA A, Santos E, Taipa R
    Balo concentric sclerosis: Literature review and report of two cases.
    J Neuroimmunol. 2024;392:578370.
    PubMed     Abstract available
    
    
    June 2024
89. LI Y, Yi JS, Guptill JT, Juel VC, et al
    Immune dysregulation in chronic inflammatory demyelinating polyneuropathy.
    J Neuroimmunol. 2024;391:578360.
    PubMed     Abstract available
    
    
    
90. RECHTMAN A, Zveik O, Haham N, Brill L, et al
    A protective effect of lower MHC-II expression in MOGAD.
    J Neuroimmunol. 2024;391:578351.
    PubMed     Abstract available
    
    
    
91. WHEELER D, Bezih M, Lannen N
    Spinocerebellar ataxia masquerading as multiple sclerosis, a case report.
    J Neuroimmunol. 2024;393:578385.
    PubMed    
    
    
    
92. YONG HYF, Batty NJ, Tottenham I, Koch M, et al
    Soluble adhesion molecules: Cognitive worsening biomarkers in primary progressive multiple sclerosis?
    J Neuroimmunol. 2024;393:578384.
    PubMed    
    
    
    May 2024
93. SRIRAM S, Kim KW, Ljunggren-Rose A
    Targeted DeSUMOylation as a therapeutic strategy for multiple sclerosis.
    J Neuroimmunol. 2024;392:578371.
    PubMed     Abstract available
    
    
    
94. GELIBTER S, Saraceno L, Pirro F, Susani EL, et al
    As time goes by: Treatment challenges in elderly people with multiple sclerosis.
    J Neuroimmunol. 2024;391:578368.
    PubMed     Abstract available
    
    
    
95. CARVER JJ, Pugh BA, Lau KM, Didonna A, et al
    Lipid metabolism is dysregulated in endocrine glands upon autoimmune demyelination.
    J Neuroimmunol. 2024;391:578366.
    PubMed     Abstract available
    
    
    April 2024
96. LI S, Sun D, Wang R, Du Q, et al
    Causal association between multiple sclerosis and severe COVID-19: A bidirectional Mendelian randomization study.
    J Neuroimmunol. 2024;391:578352.
    PubMed    
    
    
    
97. DAMMAN S, Sukpornchairak P, Ahituv A, Chen A, et al
    Unilateral cortical autoimmune encephalitis: A case series and comparison to late-onset Rasmussen's encephalitis.
    J Neuroimmunol. 2024;391:578350.
    PubMed     Abstract available
    
    
    
98. MIN YG, Ju W, Sung JJ
    Superior oblique palsy as the initial manifestation of anti-contactin-1 IgG4 autoimmune nodopathy: A case report.
    J Neuroimmunol. 2024;391:578348.
    PubMed     Abstract available
    
    
    
99. LI V, Binder MD, Purcell AW, Kilpatrick TJ, et al
    Antigen-specific immunotherapy via delivery of tolerogenic dendritic cells for multiple sclerosis.
    J Neuroimmunol. 2024;390:578347.
    PubMed     Abstract available
    
    
    
100. MUNZ C
     Altered EBV specific immune control in multiple sclerosis.
     J Neuroimmunol. 2024;390:578343.
     PubMed     Abstract available
     
     
     March 2024
101. LUO W, Wang X, Kong L, Chen H, et al
     Clinical features and prognosis of Tibetan patients with neuromyelitis optica spectrum disorder are different from those of Han Chinese patients.
     J Neuroimmunol. 2024;388:578263.
     PubMed     Abstract available
     
     
     
102. KATSU M, Sekine-Tanaka M, Tanaka M, Horai Y, et al
     Inhibition of repulsive guidance molecule-a ameliorates compromised blood-spinal cord barrier integrity associated with neuromyelitis optica in rats.
     J Neuroimmunol. 2024;388:578297.
     PubMed     Abstract available
     
     
     
103. HAHAM N, Zveik O, Rechtman A, Brill L, et al
     Altered immune co-inhibitory receptor expression and correlation of LAG-3 expression to disease severity in NMOSD.
     J Neuroimmunol. 2024;388:578289.
     PubMed     Abstract available
     
     
     
104. DE ALMEIDA GMR, de Araujo RS, Castrillo BB, Silva GD, et al
     Therapeutic plasma exchange for neuromyelitis optica attacks: Evidence and challenges from a real-world cohort from Brazil.
     J Neuroimmunol. 2024;388:578295.
     PubMed     Abstract available
     
     
     
105. CHANG EH, Hardy TA
     Peripheral oedema as an adverse effect of treatment of secondary progressive multiple sclerosis with siponimod: A case series.
     J Neuroimmunol. 2024;389:578330.
     PubMed     Abstract available
     
     
     
106. FOGEL A, Olcer M, Goel A, Feng X, et al
     Novel biomarkers and interferon signature in secondary progressive multiple sclerosis.
     J Neuroimmunol. 2024;389:578328.
     PubMed     Abstract available
     
     
     February 2024
107. KMEZIC I, Press R, Glenewinkel H, Doppler K, et al
     Low-dose rituximab treatment in a patient with anti-neurofascin-155 IgG4 autoimmune nodopathy.
     J Neuroimmunol. 2024;389:578326.
     PubMed     Abstract available
     
     
     
108. SRIWASTAVA S, Elkhooly M, Amatya S, Shrestha K, et al
     Recent advances in the treatment of primary and secondary progressive Multiple Sclerosis.
     J Neuroimmunol. 2024;390:578315.
     PubMed     Abstract available
     
     
     
109. ZHANG C, Liu R, Gao B, Li T, et al
     Efficacy and safety of low- and ultralow-dose rituximab in neuromyelitis optica spectrum disorder.
     J Neuroimmunol. 2024;387:578285.
     PubMed     Abstract available
     
     
     
110. LOTFI A, Abbasi M, Karami N, Arghavanfar H, et al
     Effects of treadmill training on myelin proteomic markers and cerebellum morphology in a rat model of cuprizone-induced toxic demyelination.
     J Neuroimmunol. 2024;387:578286.
     PubMed     Abstract available
     
     
     
111. SERAFINI B, Benincasa L, Rosicarelli B, Aloisi F, et al
     EBV infected cells in the multiple sclerosis brain express PD-L1: How the virus and its niche may escape immune surveillance.
     J Neuroimmunol. 2024;389:578314.
     PubMed     Abstract available
     
     
     
112. FRID K, Usmann A, Markovits-Pachter T, Binyamin O, et al
     Granagard administration prolongs the survival of human mesenchymal stem cells transplanted into a mouse model of multiple sclerosis.
     J Neuroimmunol. 2024;389:578313.
     PubMed     Abstract available
     
     
     
113. LI X, Chen JJ, Hur M, Paton GR, et al
     Papillitis associated with IgLON5 autoimmunity: A novel clinical phenotype.
     J Neuroimmunol. 2024;388:578312.
     PubMed     Abstract available
     
     
     
114. TIAN J, Liu X, Liang H, Shen Y, et al
     Expression of lymphocyte activation gene-3 on CD4(+)T cells is regulated by cytokine interleukin-18 in myasthenia gravis.
     J Neuroimmunol. 2024;388:578308.
     PubMed     Abstract available
     
     
     
115. GALETTA K, Ham AS, Vishnevetsky A, Bhattacharyya S, et al
     Disease modifying therapy in the treatment of tumefactive multiple sclerosis: A retrospective cohort study.
     J Neuroimmunol. 2024;388:578299.
     PubMed     Abstract available
     
     
     January 2024
116. THAKOLWIBOON S, Linnoila J, Pittock SJ, Dubey D, et al
     Cerebellar leptomeningeal enhancement: An imaging finding of rapidly progressive Purkinje cell cytoplasmic autoantibody type 1 paraneoplastic cerebellar syndrome.
     J Neuroimmunol. 2024;387:578293.
     PubMed     Abstract available
     
     
     
117. WADI L, Mandge V
     Electroconvulsive therapy for catatonia in anti-NMDA receptor encephalitis: A case series.
     J Neuroimmunol. 2024;386:578271.
     PubMed     Abstract available
     
     
     
118. CERNE D, Losa M, Mattioli P, Lechiara A, et al
     Incident anti-LGI1 autoimmune encephalitis during dementia with Lewy bodies: when Occam razor is a double-edged sword.
     J Neuroimmunol. 2024;387:578291.
     PubMed     Abstract available
     
     
     
119. PETERSEN-CHERUBINI CL, Liu Y, Deffenbaugh JL, Murphy SP, et al
     Dysregulated autotaxin expression by T cells in multiple sclerosis.
     J Neuroimmunol. 2024;387:578282.
     PubMed     Abstract available
     
     
     
120. FUJIMORI J, Nakashima I
     Early-stage volume losses in the corpus callosum and thalamus predict the progression of brain atrophy in patients with multiple sclerosis.
     J Neuroimmunol. 2024;387:578280.
     PubMed     Abstract available
     
     
     December 2023
121. BAEVA ME, Tottenham I, Koch M, Camara-Lemarroy C, et al
     Biomarkers of disability worsening in inactive primary progressive multiple sclerosis.
     J Neuroimmunol. 2023;387:578268.
     PubMed     Abstract available
     
     
     
122. STAVROGIANNI K, Kitsos DK, Giannopapas V, Chasiotis AK, et al
     Neuropsychological profiles comparison between Multiple Sclerosis patients and Multiple Sclerosis patients with overlapping features of Systemic Lupus Erythematosus.
     J Neuroimmunol. 2023;387:578270.
     PubMed     Abstract available
     
     
     
123. LI HY, Xia M, Song M, Xie Y, et al
     Rs1800629 polymorphism in TNF-alpha is associated with the susceptibility and initial short-term glucocorticoids efficacy in myasthenia gravis patients.
     J Neuroimmunol. 2023;387:578269.
     PubMed     Abstract available
     
     
     
124. HU B, Dang G, Chen S, Li S, et al
     Neuromyelitis optica spectrum disorder mimicking stroke: A case report and literature review.
     J Neuroimmunol. 2023;385:578223.
     PubMed     Abstract available
     
     
     
125. MIYAZAWA R, Fujimori J, Atobe Y, Nakashima I, et al
     CSF CXCL13 is elevated in patients with CIDP and may reflect higher disease activity.
     J Neuroimmunol. 2023;385:578238.
     PubMed     Abstract available
     
     
     
126. TESFAGIORGIS Y, Kemal EA, Craig HC, Parham KA, et al
     Systemic administration of anti-CD20 indirectly reduces B cells in the inflamed meninges in a chronic model of central nervous system autoimmunity.
     J Neuroimmunol. 2023 Dec 15:578267. doi: 10.1016/j.jneuroim.2023.578267.
     PubMed     Abstract available
     
     
     November 2023
127. CHEN Y, Wan W, Yao X, Guan Y, et al
     Drug-drug interaction between paxlovid and tacrolimus in a patient with myasthenia gravis and SARS-CoV-2 infection.
     J Neuroimmunol. 2023;385:578245.
     PubMed     Abstract available
     
     
     
128. LOWE MC, Money KM, Matthews E, Pastula DM, et al
     case of autoimmune GFAP astrocytopathy with eosinophils in the cerebrospinal fluid.
     J Neuroimmunol. 2023;385:578249.
     PubMed     Abstract available
     
     
     
129. CAO B, Li Q, Xiong L, Ruan H, et al
     Cerebrospinal fluid uric acid levels associated with disease severity in patients with anti-N-methyl-d-aspartate receptor encephalitis.
     J Neuroimmunol. 2023;384:578221.
     PubMed     Abstract available
     
     
     
130. LI Y, Liu Y, Zhao W, An X, et al
     Serum neurofilament light chain predicts spinal cord atrophy in neuromyelitis optica spectrum disorder.
     J Neuroimmunol. 2023;384:578218.
     PubMed     Abstract available
     
     
     
131. YASUDA M, Uzawa A, Kuwabara S, Suzuki S, et al
     Clinical features and outcomes of patients with muscle-specific kinase antibody-positive myasthenia gravis in Japan.
     J Neuroimmunol. 2023;385:578241.
     PubMed     Abstract available
     
     
     
132. FARAJI J, Bettenson D, Yong VW, Metz GAS, et al
     Early life stress aggravates disease pathogenesis in mice with experimental autoimmune encephalomyelitis: Support for a two-hit hypothesis of multiple sclerosis etiology.
     J Neuroimmunol. 2023;385:578240.
     PubMed     Abstract available
     
     
     October 2023
133. LEAL RATO M, Santos M, de Sa J, Ferreira J, et al
     Comorbid autoimmune disorders in people with multiple sclerosis: A retrospective cohort study.
     J Neuroimmunol. 2023;385:578226.
     PubMed     Abstract available
     
     
     
134. MOORE L, Munir A, Bae S, Miller J, et al
     Transverse myelitis associated with Mpox infection.
     J Neuroimmunol. 2023;383:578190.
     PubMed     Abstract available
     
     
     
135. KORAL G, Ulusoy C, Cossins J, Lazaridis K, et al
     Silencing of FCRLB by shRNA ameliorates MuSK-induced EAMG in mice.
     J Neuroimmunol. 2023;383:578195.
     PubMed     Abstract available
     
     
     
136. RASHED HR, Niu Z, Dyck PJ, Dyck PJB, et al
     Nerve transcriptomes in autoimmune and genetic demyelinating neuropathies: Pathogenic pathway assessment of nerve demyelination.
     J Neuroimmunol. 2023;384:578220.
     PubMed     Abstract available
     
     
     
137. KIM KW, Ljunggren-Rose A, Matta P, Toki S, et al
     Inhibition of SUMOylation promotes remyelination and reduces IL-17 mediated autoimmune inflammation: Novel approach toward treatment of inflammatory CNS demyelinating disease.
     J Neuroimmunol. 2023;384:578219.
     PubMed     Abstract available
     
     
     September 2023
138. DOMINGUEZ L, McKeon A, Tobin WO, Lopez-Chiriboga S, et al
     Long term outcomes in patients with anti-DPPX autoimmunity.
     J Neuroimmunol. 2023;384:578214.
     PubMed     Abstract available
     
     
     
139. HOLM-YILDIZ S, Dysgaard T, Krag T, Pedersen BS, et al
     Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis.
     J Neuroimmunol. 2023;384:578215.
     PubMed     Abstract available
     
     
     
140. YASUDA M, Uzawa A, Ozawa Y, Kojima Y, et al
     Serum cytokine profiles in myasthenia gravis with anti-muscle-specific kinase antibodies.
     J Neuroimmunol. 2023;384:578205.
     PubMed     Abstract available
     
     
     
141. CHENG X, Li Y, Wang Y, Sun Y, et al
     Impact of blood-brain barrier disruption on clinical features and treatment response in patients with newly diagnosed autoimmune encephalitis.
     J Neuroimmunol. 2023;383:578203.
     PubMed     Abstract available
     
     
     
142. ROSHAN HM, Valadan R, Hosseini SA, Ajami A, et al
     Specific antibodies to EBNA1 epitopes as risk factors for multiple sclerosis, a systematic review.
     J Neuroimmunol. 2023;383:578202.
     PubMed     Abstract available
     
     
     
143. CHHABRA S, Mehan S, Khan Z, Gupta GD, et al
     Matrine mediated neuroprotective potential in experimental multiple sclerosis: Evidence from CSF, blood markers, brain samples and in-silico investigations.
     J Neuroimmunol. 2023;384:578200.
     PubMed     Abstract available
     
     
     
144. MICHAEL MR, Wieske L, Koel-Simmelink MJ, van Schaik IN, et al
     Serum B-cell activating factor is not a potential biomarker for disease activity in chronic inflammatory demyelinating polyneuropathy.
     J Neuroimmunol. 2023;382:578169.
     PubMed     Abstract available
     
     
     
145. YAMAHARA N, Yoshikura N, Takekoshi A, Kimura A, et al
     Anti-N-methyl-d-aspartate receptor encephalitis preceded by meningitis lasting up to 60 days.
     J Neuroimmunol. 2023;382:578173.
     PubMed     Abstract available
     
     
     
146. NI J, Liu X, Zhang R, Wang H, et al
     Systemic administration of Shikonin ameliorates cognitive impairment and neuron damage in NPSLE mice.
     J Neuroimmunol. 2023;382:578166.
     PubMed     Abstract available
     
     
     
147. HUANG Z, Liu Y, An X, Zhang C, et al
     Rituximab induces a transient fluctuation of peripheral and follicular helper T cells in neuromyelitis optica spectrum disorder.
     J Neuroimmunol. 2023;382:578167.
     PubMed     Abstract available
     
     
     
148. ERLEBACH R, Brandi G
     Effect and timing of operative treatment for teratoma associated N-Methyl-d-Aspartate receptor-antibody encephalitis: A systematic review with meta-analysis.
     J Neuroimmunol. 2023;382:578153.
     PubMed     Abstract available
     
     
     
149. GELIBTER S, Pirro F, Saraceno L, Susani E, et al
     Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience.
     J Neuroimmunol. 2023;383:578199.
     PubMed     Abstract available
     
     
     
150. PERDAENS O, van Pesch V
     MicroRNAs are dysregulated in peripheral blood mononuclear cells in multiple sclerosis and correlate with T cell mediators.
     J Neuroimmunol. 2023;386:578196.
     PubMed     Abstract available
     
     
     August 2023
151. KHAN E, Kagzi Y, Elkhooly M, Surpur S, et al
     Disease modifying therapy and pregnancy outcomes in multiple sclerosis: A systematic review and meta-analysis.
     J Neuroimmunol. 2023;383:578178.
     PubMed     Abstract available
     
     
     
152. TERRIM S, Silva GD, de Sa E Benevides Falcao FC, Dos Reis Pereira C, et al
     Real-world application of the 2022 diagnostic criteria for first-ever episode of optic neuritis.
     J Neuroimmunol. 2023;381:578140.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.